Christopher Twelves, MD | Authors


Dr. Christopher Twelves on Eribulin Mesylate in Combination Therapies for Breast Cancer

January 05, 2016

Twelves said historically, chemotherapy combinations have been created utilizing empirical evidence, which he says is not a sound rationale for the combinations. He adds that due to certain biological properties of eribulin mesylate, the treatment warrants further investigation as a combination therapy.